Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 74

Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global nasopharyngeal cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global nasopharyngeal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global (the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan) nasopharyngeal cancer therapeutics market was valued at $53.0m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 0.5% to reach $55.0m by 2019. The existing market is strong, and is represented by three approved products – Erbitux (cetuximab), Taxotere (docetaxel) and Blenoxane (bleomycin), of which only the former is patent protected. Erbitux is currently approved in the US and European Union (EU) but not in Japan. The growth during 2006-2011 is primarily attributed to launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Although there are no molecules in the late stage of clinical development and there is an expected patent expiry of the targeted therapy drug Erbitux, the slow growth rate during the forecast period is due to the slow increase in the prevalence of nasopharyngeal cancer, which has led to an increase in the drug-treated population.

Scope

The report provides information on the key drivers and challenges of the nasopharyngeal cancer market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) nasopharyngeal cancer market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing analysis of the different Phases of development, mechanisms of action and emerging trends. Pipeline candidates for nasopharyngeal cancer fall under the following therapeutic classes: Vascular Endothelial Growth Factor (VEGF) inhibitors, Immunotherapeutic agents, cell factor receptor (c-Kit) inhibitors, VEGF and platelet-derived growth factor (PDGFR) inhibitors, Allosteric Akt inhibitor, cyclin-dependent kinase (CDK) inhibitor, Thymidylate synthase inhibitors, Toll-Like Receptor 8 (TLR8) agonists, and (Mammalian Target of Rapamycin) mTOR inhibitors.
- Analysis of the current and future competition in the global nasopharyngeal cancer market is provided. The key market players are Cyclacel Pharmaceuticals and F. Hoffman-LaRoche.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the nasopharyngeal cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in the nasopharyngeal cancer therapeutics market.

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global nasopharyngeal cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global nasopharyngeal cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global nasopharyngeal cancer market landscape? – Identify, understand and capitalize.

Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China

1
1

1.1 List of Tables
1.2 List of Figures
2 Nasopharyngeal Cancer Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Staging (TNM Classification)
2.7 Treatment
2.7.1 Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Surgery
2.7.4 Treatment by Stage of Disease
2.8 Nasopharyngeal Cancer in China
2.9 GlobalData Pipeline Report Guidance
3 Nasopharyngeal Cancer Therapeutics - Market Characterization
3.1 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Global
3.2 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Global
3.3 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – The US
3.4 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – The US
3.5 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – The UK
3.6 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – The UK
3.7 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – France
3.8 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – France
3.9 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Germany
3.10 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Germany
3.11 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Italy
3.12 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Italy
3.13 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Spain
3.14 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Spain
3.15 Nasopharyngeal Cancer Therapeutics Market Size (2006-2011) – Japan
3.16 Nasopharyngeal Cancer Therapeutics Market Forecast (2011-2019) – Japan
3.17 Drivers and Barriers for the Nasopharyngeal Cancer Therapeutic Market
3.17.1 Drivers for the Nasopharyngeal Cancer Therapeutics Market
3.17.2 Barriers for the Nasopharyngeal Cancer Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Nasopharyngeal Cancer Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Nasopharyngeal Cancer Market Marketed products profile
4.2.1 Erbitux (cetuximab)
4.2.2 Taxotere (docetaxel)
4.2.3 Blenoxane (bleomycin sulfate)
4.3 Key Takeaway
5 Nasopharyngeal Cancer Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Nasopharyngeal Cancer Pipeline Analysis – Pipeline by Clinical Phases of Development
5.3.1 Nasopharyngeal Cancer Therapeutics – Phase II Clinical Pipeline
5.3.2 Nasopharyngeal Cancer Therapeutics – Phase I Clinical Pipeline
5.4 Nasopharyngeal Cancer Pipeline by Mechanism of Action
5.5 Nasopharyngeal Cancer Technology Trends Analytical Framework
5.6 Nasopharyngeal Cancer Therapeutics – Promising Drugs under Clinical Development
5.7 Profiles of Selected Late Stage Drugs under Clinical Development
5.7.1 Seliciclib (CYC202)
5.7.2 Xeloda (capecitabine)
5.8 Key Takeaway
6 Nasopharyngeal Cancer Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials Mapping by Country (The US, EU5 and Japan)
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Clinical Trials Mapping by Overall Sponsors
6.5 Clinical Trial Mapping by Prominent Sponsors
7 Nasopharyngeal Cancer Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Global Nasopharyngeal Cancer Therapeutics - Future Players in The Market
8.1 Introduction
8.2 Company Profiles
8.2.1 Cyclacel Pharmaceuticals Inc.
8.2.2 F. Hoffmann-La Roche Ltd.
9 Nasopharyngeal Cancer Therapeutics - Appendix
9.1 Acronyms
9.2 Research Methodology
9.2.1 Coverage
9.2.2 Secondary Research
9.2.3 Forecasting
9.2.4 Primary Research
9.2.5 Expert Panel Validation
9.3 Contact Us
9.4 Disclaimer
9.5 Bibliography

1.1 List of Tables
Table 1: Nasopharyngeal Cancer, Incidence and Mortality by Country, 2011
Table 2: Nasopharyngeal Cancer - TNM Definitions
Table 3: Nasopharyngeal Cancer Staging and Treatment options Based on Stage of Disease
Table 4: Nasopharyngeal Cancer – Chemotherapy Regimens for Locally Advanced Stage (Stage II-IVB)
Table 5: Nasopharyngeal Cancer – First-Line Chemotherapy Regimens for Metastatic or Recurrent Stage (Stage IVC)
Table 6: Nasopharyngeal Cancer - Second and Third Line Chemotherapy Regimens for Metastatic or Recurrent Stage (Stage IVC)
Table 7: Nasopharyngeal Cancer Therapeutics, Global, Market Revenue, $m), 2006-2011
Table 8: Nasopharyngeal Cancer Therapeutics, Global, Revenue Forecasts ($m), 2011-2019
Table 9: Nasopharyngeal Cancer Therapeutics, the US, Market Historical Revenue ($m), 2006-2011
Table 10: Nasopharyngeal Cancer Therapeutics, the US, Revenue Forecasts ($m), 2011-2019
Table 11: Nasopharyngeal Cancer Therapeutics, the UK, Market Historical Revenue ($m), 2006-2011
Table 12: Nasopharyngeal Cancer Therapeutics, the UK, Revenue Forecasts ($m), 2011-2019
Table 13: Nasopharyngeal Cancer Therapeutics, France, Market Historical Revenue ($m), 2006-2011
Table 14: Nasopharyngeal Cancer Therapeutics, France, Revenue Forecasts ($m), 2011-2019
Table 15: Nasopharyngeal Cancer Therapeutics, Germany, Market Historical Revenue ($m), 2006-2011
Table 16: Nasopharyngeal Cancer Therapeutics, Germany, Revenue Forecasts ($m), 2011-2019
Table 17: Nasopharyngeal Cancer Therapeutics, Italy, Market Historical Revenue ($m), 2006-2011
Table 18: Nasopharyngeal Cancer Therapeutics, Italy, Revenue Forecasts ($m), 2011-2019
Table 19: Nasopharyngeal Cancer Therapeutics, Spain, Market Historical Revenue ($m), 2006-2011
Table 20: Nasopharyngeal Cancer Therapeutics, Spain, Revenue Forecasts ($m), 2011-2019
Table 21: Nasopharyngeal Cancer Therapeutics, Japan, Market Historical Revenue ($m), 2006-2011
Table 22: Nasopharyngeal Cancer Therapeutics, Japan, Revenue Forecasts ($m), 2011-2019
Table 23: Nasopharyngeal Cancer Therapeutics – Phase II Clinical Pipeline, 2011
Table 24: Nasopharyngeal Cancer Therapeutics – Phase I Clinical Pipeline, 2011
Table 25: Nasopharyngeal Cancer Therapeutics – Promising Drugs Under Clinical Development, 2011
Table 26: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Country, 2011
Table 27: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Phase, 2011
Table 28: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Status, 2011
Table 29: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011
Table 30: Nasopharyngeal Cancer Therapeutics – Clinical trials by Prominent Sponsors, 2011
Table 31: Cyclacel Pharmaceuticals Inc. – Promising Molecules in Pipeline for Nasopharyngeal Cancer, 2011
Table 32: F. Hoffmann-La Roche Ltd. – Promising Molecules in Pipeline for Nasopharyngeal Cancer, 2011

1.2 List of Figures
Figure 1: Anatomy of Nasopharynx
Figure 2: Nasopharyngeal Cancer – Stage 0
Figure 3: Nasopharyngeal Cancer – Stage I
Figure 4: Nasopharyngeal Cancer – Stage IIA (T2, N0, M0)
Figure 5: Nasopharyngeal Cancer – Stage IIB (T1 or T2, N1, M0)
Figure 6: Nasopharyngeal Cancer – Stage III
Figure 7: Nasopharyngeal Cancer – Stage IVA
Figure 8: Nasopharyngeal Cancer – Stage IVB
Figure 9: Nasopharyngeal Cancer – Stage IVC
Figure 10: Nasopharyngeal Cancer Therapeutics, Global, Market Revenue ($m), 2006-2011
Figure 11: Nasopharyngeal Cancer Therapeutics, Market Share ($m, %), 2011
Figure 12: Nasopharyngeal Cancer Therapeutics, Global, Revenue Forecasts ($m), 2011-2019
Figure 13: Nasopharyngeal Cancer Therapeutics, Forecasted Market Share ($m, %), 2019
Figure 14: Nasopharyngeal Cancer Therapeutics, the US, Market Historical Revenue ($m), 2006-2011
Figure 15: Nasopharyngeal Cancer Therapeutics, the US, Revenue Forecasts ($m), 2011-2019
Figure 16: Nasopharyngeal Cancer Therapeutics, the UK, Market Historical Revenue ($m), 2006-2011
Figure 17: Nasopharyngeal Cancer Therapeutics, the UK, Revenue Forecasts ($m), 2011-2019
Figure 18: Nasopharyngeal Cancer, France, Market Historical Revenue ($m), 2006-2011
Figure 19: Nasopharyngeal Cancer Therapeutics, France, Revenue Forecasts ($m), 2011-2019
Figure 20: Nasopharyngeal Cancer Therapeutics, Germany, Market Historical Revenue ($m), 2006-2011
Figure 21: Nasopharyngeal Cancer Therapeutics, Germany, Revenue Forecasts ($m), 2011-2019
Figure 22: Nasopharyngeal Cancer Therapeutics, Italy, Market Historical Revenue ($m), 2006-2011
Figure 23: Nasopharyngeal Cancer Therapeutics, Italy, Revenue Forecasts ($m), 2011-2019
Figure 24: Nasopharyngeal Cancer Therapeutics, Spain, Market Historical Revenue ($m), 2006-2011
Figure 25: Nasopharyngeal Cancer Therapeutics, Spain, Revenue Forecasts ($m), 2011-2019
Figure 26: Nasopharyngeal Cancer Therapeutics, Japan, Market Historical Revenue ($m), 2006-2011
Figure 27: Nasopharyngeal Cancer Therapeutics, Japan, Revenue Forecasts ($m), 2011-2019
Figure 28: Nasopharyngeal Cancer Therapeutics, Key Events Impacting Future Market, 2011
Figure 29: Opportunity and Unmet Need in the Nasopharyngeal Cancer Therapeutic Market, 2011
Figure 30: Nasopharyngeal Cancer Therapeutics Market – Strategic Competitor Assessment, 2011
Figure 31: Nasopharyngeal Cancer Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 32: Nasopharyngeal Cancer Market – Clinical Pipeline by Mechanism of Action, 2011
Figure 33: Technology Trends Analytical Framework of the Nasopharyngeal Cancer Pipeline, 2011
Figure 34: Technology Trends Analytical Framework of the Nasopharyngeal Cancer Pipeline – Description, 2011
Figure 35: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Country, 2011
Figure 36: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Phase, 2011
Figure 37: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Status, 2011
Figure 38: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011
Figure 39: Nasopharyngeal Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Figure 40: Nasopharyngeal Cancer Therapeutics, Strategic Assessment, 2011
Figure 41: Nasopharyngeal Cancer Therapeutics, Clinical Pipeline by Company, 2011
Figure 42: GlobalData market Forecasting Model, 2011

Unmet Needs in Nasopharyngeal Cancer Therapeutics Continue to Frustrate Clinicians

Clinicians treating patients with nasopharyngeal cancer may have to wait for the scientifical breakthrough they seek, as university-funded research on unique treatments may fail to offer a fast alternative, a new report by pharmaceutical market experts GlobalData has found.

The new report* shows that while the significant risks associated with current treatment options have led medical professionals to demand a new blockbuster drug, research currently being undertaken at various academic institutions around the world lacks the financial backing needed to make a considerable impact on the treatment market.

Current products for nasopharyngeal cancer put patients at risk of several adverse side effects, including neutropenia, thrombocytopenia, anemia, leucopenia and infections resulting from the loss of white blood cells. The global nasopharyngeal cancer therapeutics market therefore offers considerable opportunity for new products to capture market value if they can offer superior efficacy and safety profiles, alongside fewer adverse effects.

A slow increase in the prevalence of nasopharyngeal cancer has led to the expansion of the drug-treated population. The discovery of a curative therapy is likely to attract considerable financial rewards should pharmaceutical companies choose to explore the future market potential.

However, while the current therapeutics pipeline contains eight molecules in various stages of development, all of which are first-in-class (FIC) molecules with novel mechanisms of action, there are no molecules in the late stage of clinical development, and only three molecules are being studied within company-sponsored trials, with five others being investigated by academic institutions and universities. This makes it unlikely that these drugs will make a commercial impact on the future nasopharyngeal cancer therapeutics market.

New molecular targeted agents hold the potential to capture a significant market share, creating scope for novel drugs to enter the market. However, GlobalData’s analysis indicates that future research must show a developed understanding of the molecular and cellular processes underlying tumor biology and metastatic spread to displace the currently available treatments.

GlobalData valued the nasopharyngeal cancer therapeutics markets of the US, the UK, Germany, Italy, France, Spain and Japan market at a cumulative $53m in 2011, growing at a Compound Annual Growth Rate (CAGR) of 1.3% throughout 2006-2011. This value is forecast to increase only marginally due to the continued unmet needs of patients, growing at a CAGR of 0.5% to reach $55m by 2019.

Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global nasopharyngeal cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global nasopharyngeal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis conducted by GlobalData’s team of industry experts.

Cyclacel Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.

Customers who bought this item also bought

• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012
• Nasopharyngeal Cancer Global Clinical Trials Review, Q4, 2010
• RNA Interference (RNAi) - Global Strategic Business Report
• Global Pancreatic Cancer Pipeline Capsule - 2013
• Global Oesophageal Cancer Pipeline Capsule - 2013
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Global Head and Neck Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Bladder Cancer Epidemiology and Patient Flow Analysis - 2012